Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: Decision curve analysis to evaluate predictive models

Urology

Volumn 82, Issue 6, 2013, Pages 1355-1362

  Busetto, Gian Maria ^a   De Berardinis, Ettore ^a   Sciarra, Alessandro ^a   Panebianco, Valeria ^a   Giovannone, Riccardo ^a   Rosato, Stefano ^b   D'Errigo, Paola ^b   Di Silverio, Franco ^a   Gentile, Vincenzo ^a   Salciccia, Stefano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

AGED; AREA UNDER THE CURVE; ARTICLE; COST BENEFIT ANALYSIS; DECISION CURVE ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GENE; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEAR MAGNETIC RESONANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TRANSRECTAL ULTRASONOGRAPHY;

AGED; ANTIGENS, NEOPLASM; AREA UNDER CURVE; DECISION SUPPORT TECHNIQUES; DIGITAL RECTAL EXAMINATION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888643273     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.06.078     Document Type: Article

References (28)

1. A. Heidenreich, M. Bolla, and S. Joniau EAU guidelines on prostate cancer. European Association of Urology Eur Urol 52 2011 68 80
2. G. Sardana, B. Dowell, and E.P. Diamandis Emerging biomarkers for the diagnosis and prognosis of prostate cancer Clin Chem 54 2008 1951 1960
3. M. Auprich, A. Bjartell, and F. Chun Contemporary role of prostate cancer antigen 3 in the management of prostate cancer Eur Urol 60 2011 1045 1054
4. L.S. Marks, Y. Fradet, and I.L. Deras PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532 535
5. R.R. Goode, S.J. Marshall, and M. Duff Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients Prostate 73 2013 48 53
6. J. Ruiz-Aragón, and S. Márquez-Peláez Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis Actas Urol Esp 34 2010 346 355
7. F.K. Chun, J.I. Epstein, and V. Ficarra Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature Eur Urol 58 2010 851 864
8. R. Wang, A.M. Chinnaiyan, and R.L. Dunn Rational approach to implementation of prostate cancer antigen 3 into clinical care Cancer 115 2009 3879 3886
9. R. Kirby, and J.M. Fitzpatrick Optimising repeat prostate biopsy decisions and procedures BJU Int 109 2012 1750 1754
10. A. Sciarra, J. Barentsz, and A. Bjartell Advances in magnetic resonance imaging: how they are changing the management of prostate cancer Eur Urol 59 2011 962 977
11. A. Sciarra, V. Panebianco, and M. Ciccariello Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy Clin Cancer Res 16 2010 1875 1883
12. A. Sciarra, V. Panebianco, and S. Cattarino Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy BJU Int 110 2012 1661 1665
13. A. Sciarra, A. Autran Gomez, and S. Salciccia Biopsy-derived Gleason artifact and prostate volume: experience using ten samples in larger prostates Urol Int 80 2008 145 150
14. D. Hessels, J.M. Klein Gunnewiek, and I. van Oort DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer Eur Urol 44 2003 8 15
15. I.L. Deras, S.M. Aubin, and A. Blase PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587 1592
16. N. Lawrentschuk, and N. Fleshner The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate specific antigen levels BJU Int 103 2008 730 733
17. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
18. A.J. Vickers, and E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Med Decis Making 26 2006 565 574
19. Q. Yang, T. Liu, and R. Valdez Improvements in ability to detect undiagnosed diabetes by using information on family history among adults in the United States Am J Epidemiol 171 2010 1079 1089
20. A. Vickers, A. Cronin, and M. Roobol Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication J Clin Oncol 28 2010 2493 2498
21. M.J. Roobol, F.H. Schröder, and G.L. van Leenders Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥100) Eur Urol 58 2010 893 899
22. M. Salagierski, and J.A. Schalken Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion J Urol 187 2012 795 801
23. F.K. Chun, A. de la Taille, and H. van Poppel Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram Eur Urol 56 2009 659 667
24. M. Auprich, A. Haese, and J. Walz External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome Eur Urol 58 2010 727 732
25. S. Perdonà, V. Cavadas, and G. Di Lorenzo Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3 Eur Urol 59 2011 81 87
26. P. Pepe, and F. Aragona PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy Anticancer Res 31 2011 4445 4449
27. C.M. Moore, N.L. Robertson, and N. Arsanious Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review Eur Urol 63 2013 125 140
28. F.H. Schröder, J. Hugosson, M.J. Roobol for the ERSPC Investigators Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328